Table 2.
Odds ratios and 95% confidence intervals for associations between clinical and tumor characteristics and status of Intraluminal Tumor Cell involvement of the fallopian tube in 371 endometrial carcinoma cases
| All (n=371) | ILTC status | ||||||
|---|---|---|---|---|---|---|---|
| Absent (n=315) | Present (n=56) | ||||||
| n (%) | n (%)a | n (%)a | OR (95% CI)b | p-valuec | OR (95% CI)d | p-valuec | |
| Age | 0.48 | ---- | |||||
| <55 | 55 (14.8) | 49 (89.1) | 6 (10.9) | 1.00 | |||
| 55–64 | 136 (36.7) | 112 (82.4) | 24 (17.7) | 1.75 (0.67, 4.55) | |||
| ≥65 | 180 (48.5) | 154 (85.6) | 26 (14.4) | 1.38 (0.54, 3.54) | |||
| BMI (kg/m2)e | 0.16 | ---- | |||||
| Normal weight (<25) | 84 (22.6) | 72 (85.7) | 12 (14.3) | 1.00 | |||
| Overweight (25–29.9) | 78 (21.0) | 60 (76.9) | 18 (23.1) | 0.80 (0.37, 1.73) | |||
| Obese (≥30) |
170 (45.8) | 150 (88.2) | 20 (11.8) | 1.80 (0.80, 4.03) | |||
| Surgery | 0.50 | ---- | |||||
| Abdominal H | 277 (74.7) | 237 (85.6) | 40 (14.4) | 1.00 | |||
| LAVH | 76 (20.5) | 64 (84.2) | 12 (15.8) | 1.11 (0.55, 2.24) | |||
| Vaginal H | 9 (2.4) | 6 (66.7) | 3 (33.3) | 2.96 (0.71, 12.33) | |||
| TLH | 9 (2.4) | 8 (88.9) | 1 (11.1) | 0.74 (0.09, 6.08) | |||
| Peritoneal cytology f | 0.13 | ---- | |||||
| None | 334 (90.3) | 284 (85.0) | 50 (15.0) | 1.00 | |||
| Negative for malignancy | 29 (7.8) | 26 (89.7) | 3 (10.3) | 0.66 (0.19, 2.25) | |||
| Positive for malignancy | 7 (1.9) | 4 (57.1) | 3 (42.9) | 4.26 (0.93, 19.61) | |||
| FIGO Stage | <0.0001 | <0.0001 | |||||
| 1 | 231 (62.3) | 216 (93.5) | 15 (6.5) | 1.00 | 1.00 | ||
| 2 | 19 (5.1) | 15 (79.0) | 4 (21.1) | 1.28 (1.17, 1.39) | 4.22 (1.23, 14.53) | ||
| 3 | 83 (22.4) | 63 (75.9) | 20 (24.1) | 4.57 (2.21, 9.45) | 4.65 (2.10, 10.26) | ||
| 4 | 38 (10.2) | 21 (55.3) | 17 (44.7) | 11.66 (5.10, 26.64) | 11.21 (4.18, 30.04) | ||
| Myometrial invasion | 0.01 | ---- | |||||
| Less than half | 197 (53.1) | 176 (89.3) | 21 (10.7) | 1.00 | |||
| Half or more | 174 (46.9) | 139 (79.9) | 35 (20.1) | 2.11 (1.18, 3.79) | |||
| LVSI | 0.002 | ---- | |||||
| Absent | 204 (55.0) | 184 (90.2) | 20 (9.8) | 1.00 | |||
| Present | 167 (45.0) | 131 (78.4) | 36 (21.6) | 2.53 (1.40, 4.56) | |||
| Histotype | 0.02 | 0.63 | |||||
| Low-grade endometrioid | 146 (39.3) | 132 (90.4) | 14 (10.0) | 1.00 | 1.00 | ||
| High-grade endometrioid | 75 (20.2) | 65 (86.7) | 10 (13.3) | 1.45 (0.61, 3.44) | 0.79 (0.31, 2.03) | ||
| Serous | 73 (19.7) | 52 (71.2) | 21 (28.8) | 3.81 (1.80, 8.05) | 1.35 (0.54, 3.37) | ||
| Carcinosarcoma | 34 (9.2) | 29 (85.3) | 5 (14.7) | 1.63 (0.54, 4.87) | 0.64 (0.19, 2.14) | ||
| Clear cell | 20 (5.4) | 19 (95.0) | 1 (5.0) | 0.50 (0.06, 3.99) | 0.24 (0.03, 2.12) | ||
| Mixed epithelial | 20 (5.4) | 16 (80.0) | 4 (20.0) | 2.36 (0.69, 8.04) | 1.07 (0.28, 4.13) | ||
| Undifferentiated | 3 (0.8) | 2 (66.7) | 1 (33.3) | 4.71 (0.40, 55.34) | 0.60 (0.04, 8.31) | ||
| Radiation | 0.76 | ---- | |||||
| None | 306 (82.5) | 259 (84.6) | 47 (15.4) | 1.00 | |||
| Any | 65 (17.5) | 56 (86.2) | 9 (13.9) | 0.89 (0.41, 1.91) | |||
| Chemotherapy | <0.0001 | ---- | |||||
| None | 218 (58.8) | 202 (92.7) | 16 (7.3) | 1.00 | |||
| Any | 153 (41.2) | 113 (73.9) | 40 (26.1) | 4.47 (2.40, 8.34) | |||
Abbreviations and symbols: ILTCs=intraluminal tumor cells, BMIe=body mass index and data missing for n=39 cases, H=hysterectomy, LAVH=laparoscopic assisted vaginal hysterectomy, TLH=total laparoscopic hysterectomy, LVSI= Lymph-vascular space invasion, Peritoneal cytologyf=data missing for n=1case, CI=Confidence intervals,
Row percentage,
Unadjusted Odds Ratios (ORs) and 95% Confidence Intervals (CIs),
Wald chi-square p-value,
ORs and 95% CIs adjusted for age (<55, 55–64, ≥65), FIGO 2009 stage (1, 2, 3, 4), LVSI (no vs. yes), and histotype (low-grade endometrioid, high-grade endometrioid, serous, carcinosarcoma, clear cell, mixed epithelial, undifferentiated)